AsianFin -- Bristol Myers Squibb (BMS) has agreed to sell its controlling stake in a historic joint venture with Shanghai Pharmaceuticals Holding and Sinopharm Group, marking the end of the first-ever US pharmaceutical partnership in China.
The New York–based drugmaker has signed a deal to divest its 60 percent stake in Sino-American Shanghai Bristol-Myers Squibb Pharmaceutical, better known as the SASS Plant, a company insider told Yicai. The identity of the buyer was not disclosed.
According to the insider, the decision is aimed at better aligning BMS’s global resource allocation and optimizing its regional strategy to ensure that the company’s medicines remain available to patients in China and worldwide on a sustainable basis.
Founded in 1982, the SASS Plant was established shortly after China began its economic reform and opening-up, symbolizing a milestone in Sino-US business cooperation. The venture primarily produces off-patent drugs such as Cefradine Capsules and Metformin Hydrochloride Tablets, which have long been staples in China’s healthcare system.
Explore more exclusive insights at nextfin.ai.
Insights
What is the significance of the Bristol Myers Squibb and Shanghai Pharmaceuticals joint venture?
When was the SASS Plant established and what historical context influenced its creation?
What are the key products manufactured by the SASS Plant?
How does this divestment align with Bristol Myers Squibb's global strategy?
What impact will the sale of BMS's stake have on the availability of medicines in China?
What challenges did Bristol Myers Squibb face in maintaining its stake in the joint venture?
How does the SASS Plant represent Sino-US business cooperation over the years?
What has been the market response to Bristol Myers Squibb's decision to divest?
Are there any recent regulatory changes affecting foreign pharmaceutical companies in China?
What long-term implications could this divestment have on the pharmaceutical industry in China?
How does the sale of BMS's stake compare to other foreign pharmaceutical companies operating in China?
What are the potential risks and benefits of foreign companies investing in China’s pharmaceutical sector?
How have Sino-US relations influenced the pharmaceutical industry in both countries?
What historical examples exist of foreign companies divesting from joint ventures in China?
What are the competitive advantages that local pharmaceutical companies might gain from this divestment?
